Zelluna ASA [ZLNA]: Annual Report 2024
Werte in diesem Artikel
Oslo, Norway, 02 April, 2025 - Zelluna ASA, a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces that the Board of Directors of Zelluna ASA has approved the Annual Report for 2024.
Please find a PDF version of the annual report, as well as the report in European Single Electronic Format (ESEF), as attachments to this release. The Annual Report is also available at the company's website: www.zelluna.com
This information is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.
For further information, please contact:
Anders Tuv, Chairman of the Board of Directors of Zelluna ASA
Email: at@radforsk.no
Phone: +47 982 06 826
Namir Hassan, CEO, Zelluna ASA
Email: namir.hassan@zelluna.com
Phone: +44 7720 687608
Hans Vassgård Eid, CFO, Zelluna ASA
Email: hans.eid@zelluna.com
Phone: +47 482 48632
Attachments
Ausgewählte Hebelprodukte auf Ultimovacs AS Registered
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Ultimovacs AS Registered
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Nachrichten zu Ultimovacs AS Registered Shs
Analysen zu Ultimovacs AS Registered Shs
Keine Analysen gefunden.